27 May 2025 – C4X Discovery Holdings Ltd ("C4XD"), a pioneering Drug Discovery company, today announces that it has received a milestone payment of €8 million from Sanofi [EPA: SAN], reflecting ...
22 September 2025 – C4X Discovery Holdings Ltd ("C4XD"), a pioneering Drug Discovery company, today announces the selection of a potential best-in-class pre-clinical candidate from its oral α4β7 ...
C4X Discovery Holdings Ltd. has selected a preclinical candidate from its oral α4β7 integrin inhibitor program for the treatment of inflammatory bowel disease (IBD). The potent and selective α4β7 ...
C4X Discovery announces selection of a once-daily development candidate from its a4ß7 inhibitor programme A potent and selective a4ß7 inhibitor with oral bioavailability to support once-daily dosing ...
€8 million milestone payment triggered by pre-clinical progression in oral IL-17A inhibitor programme 27 May 2025 - C4X Discovery Holdings Ltd ("C4XD"), a pioneering Drug Discovery company, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results